DrugBiological
Racotumomab clinical trials
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2009 (1)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses racotumomab is read from its arms, and is right about nine times in ten.
Testing it · 4
- Racotumomab in Patients With High-risk NeuroblastomaCompletedPhase 2Laboratorio Elea Phoenix S.A.NCT02998983Written as Racotumomab
- Immunotherapy With Racotumomab in Advanced Lung CancerStatus unknownPhase 3Recombio SLNCT01460472Written as Racotumomab
- Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated GangliosidesCompletedPhase 1Laboratorio Elea Phoenix S.A.NCT01598454Written as racotumomab
- Immunotherapy With Racotumomab Versus Support Treatment in Advanced Non-small Cell Lung Cancer PatientsCompletedPhase 2Laboratorio Elea Phoenix S.A.NCT01240447Written as racotumomab
Codes
What other systems call racotumomab · ClinicalTrials.gg INT000041
- MeSH (NLM) C000590234racotumomabOne source NLM
- UNII (FDA) 52G405U1E5RACOTUMOMABConfirmed FDA, NLM, Wikidata
- Wikidata Q7279820racotumomabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C95024RacotumomabOne source FDA
- DrugBank DB13045One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000590234 | racotumomab | One source NLM |
| UNII (FDA) | 52G405U1E5 | RACOTUMOMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7279820 | racotumomab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C95024 | Racotumomab | One source FDA |
| DrugBank | DB13045 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.